Form 4: Incyte Corp Executive Matteo Trotta Reports Stock and Option Awards

EVP Matteo Trotta reports acquisition of restricted stock units and stock options in Incyte Corp.

Summary

• Matteo Trotta, EVP, GM, Dermatology US of Incyte Corp, reported changes in beneficial ownership on March 25, 2024.
• Trotta was awarded 7,828 restricted stock units (RSUs) that vest 25% annually over four years.
• These RSUs can be settled for common stock on a one-for-one basis.
• Trotta also acquired 21,868 employee stock options with an exercise price of $57.48, exercisable starting March 25, 2025, and expiring on March 25, 2034.
• The options vest with 25% after one year and the remainder monthly over three years.
• Following the reported transactions, Trotta beneficially owns 7,828 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested and 21,868 derivative securities.

Sentiment

Score: 6

Explanation: The document is a routine disclosure of executive compensation. It's neutral in tone and doesn't indicate any significant positive or negative developments for the company.

Positives

• The grant of RSUs and stock options to an executive suggests the company is incentivizing performance and aligning executive interests with shareholder value.

Future Outlook

The vesting schedule of the RSUs and stock options indicates a long-term incentive plan for the executive, aligning their interests with the company's performance over the next four years.

Industry Context

Stock and option awards are a common practice in the pharmaceutical industry to attract, retain, and incentivize key executives. The vesting schedules are designed to align executive compensation with long-term company performance.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotechnology and pharmaceutical industries.
• Companies like Amgen, Gilead Sciences, and Regeneron Pharmaceuticals also utilize stock options and restricted stock units to incentivize their executives.
• The vesting schedules, typically ranging from three to five years, are consistent with industry norms.

Stakeholder Impact

• The stock and option awards could have a minor dilutive effect on existing shareholders.
• The awards incentivize the executive to improve company performance, which could benefit all stakeholders.

Key Dates